Spinogenix is a clinical-stage biotechnology company developing novel neuroprotective therapies for Alzheimer's disease and related neurodegenerative disorders. The company's therapeutic approach centers on microtubule stabilization and synaptic resilience — downstream mechanisms that are disrupted across multiple neurodegenerative diseases regardless of their specific protein pathologies. This positions Spinogenix's pipeline as potential disease-modifying treatments with broad applicability across patient populations.
Company Overview
Mermaid diagram (expand to render)
| Attribute | Details |
|-----------|--------|
| Founded | ~2019-2020 (estimated) |
| Headquarters | United States |
| Stage | Clinical-stage |
| Focus | Neuroprotection, microtubule stabilization, synaptic resilience |
| Lead Program | SPG302 (Phase 1 in AD) |
Microtubule Stabilization
Spinogenix's lead mechanism targets the stabilization of neuronal microtubules[@brunden2020][@kozlovski2022]:
The microtubule dysfunction problem: In Alzheimer's disease and related neurodegenerative conditions, microtubules — the structural scaffolding of neurons — become progressively destabilized through:
- Tau hyperphosphorylation: Phosphorylated tau loses affinity for microtubules, leading to their depolymerization
- Axonal transport deficits: Unstable microtubules impair the movement of organelles, vesicles, and signaling complexes along axons
- Synaptic degeneration: Cytoskeletal disruption contributes to synaptic loss — the strongest anatomical correlate of cognitive decline
- Energy depletion: Impaired axonal transport forces neurons to expend excess energy compensating for logistics failures
Therapeutic approach: Spinogenix compounds are designed to directly stabilize microtubules, bypassing upstream pathology (amyloid, tau) to address the common downstream convergence point of neurodegeneration. This mechanism has demonstrated efficacy in preclinical models of tauopathy and axonal degeneration[@brunden2020].
Synaptic Resilience
Beyond microtubule stabilization, Spinogenix is developing compounds that enhance synaptic resilience[@moreno2023]:
- Synapse preservation: Protecting synaptic structures from degeneration even in the presence of pathological proteins
- Metabolic support: Maintaining neuronal energy production and protein synthesis capacity
- Calcium homeostasis: Stabilizing intracellular calcium dynamics that become dysregulated in neurodegeneration
Pipeline Programs
SPG302 — Phase 1 in Alzheimer's Disease
SPG302 is a first-in-class neuroprotective compound targeting microtubule stabilization and synaptic resilience, currently in Phase 1 clinical evaluation for mild-to-moderate Alzheimer's disease (NCT06427668)[@spinogenix_pipeline].
Clinical development:
- Indication: Mild-to-moderate Alzheimer's disease (MMSE 16-26)
- Phase: Phase 1 (active, not recruiting as of 2026)
- Route: Oral (tablet)
- Primary endpoints: Safety, tolerability, pharmacokinetics
- Secondary endpoints: CSF biomarkers (neurogranin, NfL, tau), cognitive measures
Rationale for mild-to-moderate population: Unlike anti-amyloid antibodies targeting early/prodromal stages, SPG302 addresses downstream pathology (microtubule destabilization, synaptic loss) that remains therapeutically relevant in established disease. Patients with mild-to-moderate AD still have viable synapses that can be protected, and microtubule stabilization addresses a convergence point of multiple upstream pathogenic pathways[@kozlovski2022][@vanelderen2024].
SPG301 — Preclinical in ALS/FTD
SPG301 is in preclinical development for [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) and [frontotemporal dementia](/diseases/frontotemporal-dementia)[@spinogenix_pipeline].
Scientific rationale:
- TDP-43 pathology in ALS/FTD causes microtubule disruption and axonal transport failure
- C9orf72 repeat expansion leads to similar cytoskeletal deficits
- VCP mutations disrupt endosomal-lysosomal pathways, compounding microtubule instability
- Microtubule stabilization addresses these convergent mechanisms
Preclinical data: Studies in ALS/FTD cellular and animal models have demonstrated that microtubule-stabilizing agents can protect motor neurons and cortical neurons from TDP-43-mediated toxicity.
SPG303 — Discovery in Parkinson's Disease
SPG303 is in the discovery stage for [Parkinson's disease](/diseases/parkinsons-disease)[@spinogenix_pipeline].
Scientific rationale:
- Alpha-synuclein aggregation disrupts microtubule networks
- LRRK2 mutations cause phosphorylation of Rab GTPases that regulate microtubule-based transport
- Axonal degeneration in PD involves prominent cytoskeletal disruption
- Microtubule stabilization may protect dopaminergic neurons from multiple converging insults
Competitive Positioning
Spinogenix's neuroprotective approach contrasts with the dominant therapeutic strategy in Alzheimer's disease — targeting amyloid-beta through monoclonal antibodies.
| Approach | Target | Mechanism | Stage | Limitations |
|---------|--------|-----------|-------|------------|
| Spinogenix (SPG302) | Downstream / shared | Microtubule stabilization | Phase 1 | Novel mechanism, unproven in humans |
| Anti-amyloid antibodies (lecanemab, donanemab) | Upstream / specific | Aβ clearance | Approved | Early-stage only, ARIA, infusion |
| Tau-targeted therapies | Midstream / specific | Tau pathology | Phase 2/3 | Limited efficacy so far |
| Symptomatic agents (cholinesterase inhibitors) | Symptomatic | Acetylcholine modulation | Approved | Temporary, modest benefit |
Key differentiation: SPG302 addresses a downstream mechanism that is disrupted across essentially all neurodegenerative diseases, making it potentially applicable to patients regardless of their amyloid or tau status. This is a fundamentally different strategy from pathology-specific approaches[@chen2025ad].
Historical Context
Failed Microtubule Stabilization Programs
Multiple prior attempts to develop microtubule-stabilizing agents for AD have encountered challenges[@brunden2020]:
- Tideglusib (NP031112): GSK-3β inhibitor, failed Phase 2
- Davunetide (NAPVSIPQ): NPTX2-derived peptide, failed in PSP
- Epothilone D (BMS-986168): Failed due to peripheral toxicity
- Methylene blue derivatives: Mixed results, formulation challenges
Why Spinogenix's Approach May Succeed
Spinogenix's platform may address limitations of prior programs:
- Improved compound properties: SPG compounds designed with better CNS penetration and tolerability profiles
- Disease-stage targeting: SPG302 positioned for mild-to-moderate AD where synaptic loss is active but neurons are still viable
- Synaptic resilience focus: Beyond microtubule stabilization, compounds enhance synaptic protective pathways
- Oral administration: Tablet formulation avoids infusion center requirements and ARIA monitoring needed for antibody therapies
Mechanism Connection
Spinogenix compounds intersect multiple NeuroWiki mechanisms:
- [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction-hypothesis) — Primary target of SPG302
- [Tau Phosphorylation Pathway](/mechanisms/tau-phosphorylation-pathway) — Microtubule stabilization addresses tau-mediated destabilization
- [Axonal Transport Deficit](/mechanisms/axonal-transport-deficit) — Direct consequence of microtubule destabilization
- [Neuronal Energy Metabolism](/mechanisms/neuronal-energy-metabolism) — Synaptic resilience supports metabolic function
- [Microtubule Destabilization](/mechanisms/microtubule-destabilization-ad) — Direct therapeutic target
Cross-Links
- [SPG302 Phase 1 AD Trial](/clinical-trials/spg302-phase1-ad-nct06427668) — Lead clinical program
- [Alzheimer's Disease](/diseases/alzheimers-disease) — Primary indication
- [ALS](/diseases/amyotrophic-lateral-sclerosis) — SPG301 indication
- [FTD](/diseases/frontotemporal-dementia) — SPG301 indication
- [Parkinson's Disease](/diseases/parkinsons-disease) — SPG303 discovery
- [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction-hypothesis) — Mechanism focus
- [Microtubule-Stabilizing Agents](/therapeutics/microtubule-stabilizing-agents-ad) — Therapeutic class
- [Neuroprotective Strategies](/therapeutics/neuroprotective-approaches-ad) — Broader therapeutic context
References
[Spinogenix](https://www.spinogenix.com)[@spinogenix_web]
[Spinogenix Pipeline](https://www.spinogenix.com/pipeline)[@spinogenix_pipeline]
[Alzheimer's disease drug development pipeline: 2024 (Alzheimer's Dement., 2024)](https://doi.org/10.1002/alz.13859)[@cummings2024]
[Stabilization of microtubules in AD (Nat Rev Drug Discov., 2020)](https://doi.org/10.1038/nrd.2020.123)[@brunden2020]
[Synaptic resilience as therapeutic target (Brain, 2023)](https://doi.org/10.1093/brain/awad256)[@moreno2023]
[Neuroprotective strategies in AD: emerging targets (Trends Neurosci., 2024)](https://doi.org/10.1016/j.tins.2024.03.012)[@vanelderen2024]
[Microtubule-stabilizing agents in neurodegenerative disease (Neuropharmacology, 2022)](https://doi.org/10.1016/j.neuropharm.2022.109012)[@kozlovski2022]
[Novel neuroprotective compounds in early AD trials (Alzheimers Res Ther., 2025)](https://doi.org/10.1186/s13195-025-01789-5)[@chen2025ad]